Images List Premium Download Classic

Factor VIII

Factor VIII-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Factor viii polymer conjugates
Baxalta Gmbh
June 08, 2017 - N°20170157259

The invention is a proteinaceous construct comprising a factor viii molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of factor viii, and methods of preparing same.
Modified von willebrand factor
Csl Limited
June 01, 2017 - N°20170152300

The present invention provides a modified polypeptide which binds factor viii. The modified polypeptide comprises a sequence as shown in seq id no:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to factor viii with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified seq ...
Antibody substituting for function of blood coagulation factor viii
Csl Limited
May 25, 2017 - N°20170145111

The present inventors produced a variety of bispecific antibodies that specifically bind to both f. Ix/f. Ixa and f. X, and functionally substitute for f. Viiia, i. E., have a cofactor function to promote f. X activation via f. Ixa. Among these antibodies, the antibody a44/b26 reduced coagulation time by 50 seconds or more as compared to that observed ...
Factor VIII Patent Pack
Download + patent application PDFs
Factor VIII Patent Applications
Download + Factor VIII-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Factor VIII-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Liver-specific constructs, factor viii expression cassettes and methods of use thereof
Sangamo Biosciences, Inc.
May 04, 2017 - N°20170119906

Described herein are constructs used for liver-specific expression of a transgene.
Method of administering porcine b-domainless fviii
Baxalta Incorporated
May 04, 2017 - N°20170119857

The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, ...
Adeno-associated virus factor viii vectors
Biomarin Pharmaceutical Inc.
April 06, 2017 - N°20170095538

The invention provides improved adeno-associated virus (aav) factor viii (fviii) vectors, including aav fviii vectors that produce a functional factor viii polypeptide and aav fviii vectors with high expression activity.
Factor VIII Patent Pack
Download + patent application PDFs
Factor VIII Patent Applications
Download + Factor VIII-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Factor VIII-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Factor viii formulations
University Of Connecticut
March 30, 2017 - N°20170087218

A factor viii (fviii) composition formulated such that nacl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized fviii.
Stabilization of factor viii without calcium as an excipient
Advantech Bioscience FarmacÊutica Ltda
March 23, 2017 - N°20170080059

The present invention provides a novel albumin-free formulation of recombinant factor viii that does not require calcium ions as an added formulation excipient. The absence of calcium chloride in the formulation results in a number of improvements and benefits for a factor viii formulation. This invention allows a factor viii formulation that can be lyophilized more efficiently as the absence ...
Factor viii chimeric proteins and uses thereof
Biogen Ma Inc.
March 16, 2017 - N°20170073393

The present invention provides a chimeric protein comprising a first polypeptide which comprises a fviii protein and a first ig constant region or a portion thereof and a second polypeptide which comprises a vwf protein comprising the d′ domain and d3 domain of vwf, a xten sequence having less than 288 amino acids in length, and a second ig constant ...
Enhancement of recombinant protein expression with copper
Advantech Bioscience Farmacêutical Ltda
March 09, 2017 - N°20170067013

The present invention provides a novel use of copper (cupric ion) for improved cell expression of recombinant proteins, particularly coagulation proteins such as recombinant factor viii, b domain deleted recombinant factor viii, recombinant factor ix and rfvii or rfviia. The use of such cell culture supplement results in higher productivity and robustness of the manufacturing process. This invention results in ...
Factor viii variants having a decreased cellular uptake
Sanquin Blood Supply Foundation
March 09, 2017 - N°20170066813

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied factor viii molecules having decreased cellular uptake.
Stable factor viii formulations with low sugar-glycine
Advantech Bioscience Farmacêutica Ltda
March 09, 2017 - N°20170065683

The present invention provides a novel albumin-free preparation of factor viii has a high amount of salt and a low concentration of sugar and of glycine. The high salt provides stability and an elegant cake structure as the major crystalline component. The sugar and glycine provide a complex amorphous matrix together with some amorphous non-crystallized salt for stabilization of factor ...
Factor viii b cell epitope variants having reduced immunogenicity
Bloodworks
February 23, 2017 - N°20170051041

Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.
Factor VIII Patent Pack
Download + patent application PDFs
Factor VIII Patent Applications
Download + Factor VIII-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Factor VIII-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Nucleic acid encoding bispecific antibodies
Chugai Seiyaku Kabushiki Kaisha
January 26, 2017 - N°20170022293

Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules ...
Factor viii molecules with reduced vwf binding
Novo Nordisk A/s
January 26, 2017 - N°20170020992

The present invention relates to a recombinant factor viii molecule, wherein said molecule has reduced vwf binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
Factor viii fusion protein
Novo Nordisk A/s
January 19, 2017 - N°20170015729

The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated factor viii molecules fused to a polypeptide such as e. G. An antibody binding protein or a fc domain.
Novel albumin-free factor viii formulations
University Of Connecticut
January 05, 2017 - N°20170000854

A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering ...
Factor viii compositions and methods of making and using same
Amunix Operating Inc.
December 29, 2016 - N°20160376344

The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.
Lipid nanodiscs and nanorods as modulators of clotting factor function in vivo
Board Of Regents, The University Of Texas System
December 22, 2016 - N°20160367677

The present invention includes composition and methods of using a lipid nanodisk or nanotube composition comprising a lipid composition of phosphatidylserine and galactosylceramide and a membrane-bound factor viii protein, a membrane-bound factor ix protein, a membrane-bound factor viii-factor ix protein complex, or a membrane-bound factor v-factor x protein complex in or about the lipid nanodisks or nanotubes.
Method for improving the stability of purified factor viii after reconstitution
Csl Limited
December 22, 2016 - N°20160367641

The present disclosure relates to a method for increasing the stability of a factor viii molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the factor viii molecule into a first fragment comprising essentially the a1 domain and the a2 domain and a second fragment comprising essentially the a3 domain, the c1 domain and the c2 domain throughout ...
Recombinant factor viii proteins
Biogen Idec Ma Inc.
December 08, 2016 - N°20160355568

Provided are recombinant factor viii proteins, e. G., human factor viii proteins with heterologous moieties inserted into flexible permissive loops located in the factor viii a domains, while retaining the procoagulant activity of factor viii.
Loading